% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pajtler:119351,
      author       = {K. Pajtler$^*$ and S. C. Mack and V. Ramaswamy and C. A.
                      Smith and H. Witt$^*$ and A. Smith and J. R. Hansford and K.
                      von Hoff and K. D. Wright and E. Hwang and D. Frappaz and Y.
                      Kanemura and M. Massimino and C. Faure-Conter and P. Modena
                      and U. Tabori and K. E. Warren and E. C. Holland and K.
                      Ichimura and F. Giangaspero and D. Castel and A. von
                      Deimling$^*$ and M. Kool$^*$ and P. B. Dirks and R. G.
                      Grundy and N. K. Foreman and A. Gajjar and A. Korshunov$^*$
                      and J. Finlay and R. J. Gilbertson and D. W. Ellison and K.
                      D. Aldape and T. E. Merchant and E. Bouffet and S.
                      Pfister$^*$ and M. D. Taylor},
      title        = {{T}he current consensus on the clinical management of
                      intracranial ependymoma and its distinct molecular
                      variants.},
      journal      = {Acta neuropathologica},
      volume       = {133},
      number       = {1},
      issn         = {1432-0533},
      address      = {Berlin},
      publisher    = {Springer},
      reportid     = {DKFZ-2017-00106},
      pages        = {5 - 12},
      year         = {2017},
      note         = {Consensus Paper},
      abstract     = {Multiple independent genomic profiling efforts have
                      recently identified clinically and molecularly distinct
                      subgroups of ependymoma arising from all three anatomic
                      compartments of the central nervous system (supratentorial
                      brain, posterior fossa, and spinal cord). These advances
                      motivated a consensus meeting to discuss: (1) the utility of
                      current histologic grading criteria, (2) the integration of
                      molecular-based stratification schemes in future clinical
                      trials for patients with ependymoma and (3) current therapy
                      in the context of molecular subgroups. Discussion at the
                      meeting generated a series of consensus statements and
                      recommendations from the attendees, which comment on the
                      prognostic evaluation and treatment decisions of patients
                      with intracranial ependymoma (WHO Grade II/III) based on the
                      knowledge of its molecular subgroups. The major consensus
                      among attendees was reached that treatment decisions for
                      ependymoma (outside of clinical trials) should not be based
                      on grading (II vs III). Supratentorial and posterior fossa
                      ependymomas are distinct diseases, although the impact on
                      therapy is still evolving. Molecular subgrouping should be
                      part of all clinical trials henceforth.},
      cin          = {B062 / L101 / G380},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)L101-20160331 /
                      I:(DE-He78)G380-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27858204},
      pmc          = {pmc:PMC5209402},
      doi          = {10.1007/s00401-016-1643-0},
      url          = {https://inrepo02.dkfz.de/record/119351},
}